Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $317M (up 19.2% year over year) with net income of $89M.
Q1 2026 key financials · XBRL
- Revenue
- $317M
- +19.2% YoY
- Net income
- $89M
- +89.4% YoY
- Operating margin
- 43.2%
- Gross margin
- 87.4%
- EPS (diluted)
- $0.69
- +81.6% YoY
Source: XBRL data from the Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 10-Q on SEC EDGAR. USD.
Indivior Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Convertible Senior Notes due 2031 issued March 17, 2026, creating new debt-related exposure
- $400 million share-repurchase authorization announced February 26, 2026, with $275 million remaining at March 31, 2026
- Insider 10b5-1 plans cover 141,758 shares, with sales prohibited until after May 11, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Indivior Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.